In 2018, Rosendahl et al. found that the resistin-receptor, adenylyl cyclase-associated protein-1 (CAP1), was expressed across different breast cancer subtypes, with higher expression found in ER-negative tumors compared to ER-positive tumors [60]. The gene discussed is CAP1; the disease is breast carcinoma.